Myomo (MYO) Insider Morris Milton Mayo Buys 78,704 Shares

Morris Milton Mayo, a notable insider, purchased 78,704 shares of Myomo, Inc. on June 25, 2026. This move indicates a potential vote of confidence in the company's future prospects.

Other Institutional Activity in Myomo, Inc.

Rosalind Advisors, Inc. grew its holdings by 7,500 shares, ending with 3,847,272 shares worth about $2,599,217. BlackRock, Inc. reduced its position by 24,389 shares, holding 1,688,390 shares valued at $1,140,675. Vanguard Capital Management LLC opened a new position with 1,144,324 shares worth $773,563. Geode Capital Management, LLC increased its stake by 121,830 shares, totaling 858,799 shares valued at $580,274. Jefferies Financial Group Inc. maintained its position at 704,275 shares, valued at $475,808.

Myomo, Inc. Stock Down 28.2%

Shares of NYSE American:MYO traded near $1.14 on Saturday. Myomo, Inc. has a market cap of approximately $39.8 million and a forward P/E ratio of -4.07, indicating it isn't currently profitable. The stock has a 52-week range between $0.60 and $2.38. It also has a 50-day moving average of $1.02 and a 200-day moving average of $0.92. The company's current ratio is 2.73, and its quick ratio is 2.19, with a debt-to-equity ratio of 210.65.

Recent Earnings

In its latest financial results, Myomo, Inc. reported revenue of $41.2 million, reflecting a modest growth of 2.9%. The company posted a net margin of -36.7% and a return on equity of -98.5%. The next earnings announcement is scheduled for August 10, 2026.

Insider Buying and Selling at Myomo, Inc.

On June 25, 2026, several insiders, including Kirk Thomas, William Febbo, Morris Milton Mayo, Heather Getz, Joseph Manko Jr., and Thomas Aloysius Jr., each bought 78,704 shares. These transactions were not executed under a Rule 10b5-1 plan, suggesting they were discretionary buys.

Analysts Set New Price Targets

On June 8, 2026, Ascendiant Capital maintained a 'buy' rating for Myomo, Inc. with a price target of $10. The consensus among five analysts is a 'buy' recommendation, with a mean target price of $4.42.

About Myomo, Inc.

Myomo, Inc. is a healthcare company based in Burlington, Massachusetts, specializing in wearable medical robotics. The company designs and manufactures myoelectric orthotics to assist individuals with neuromuscular disorders. Its main product, MyoPro, helps support weak or paralyzed arms, enhancing daily functional activities. Myomo operates in the United States, Germany, and other international markets, reaching customers through various sales channels, including orthotics and prosthetics providers.

Bottom Line

Morris Milton Mayo's purchase of Myomo shares on June 25, 2026, is a noteworthy insider transaction. Investors often track such insider activities as they can hint at the confidence insiders have in the company's future. As a reminder, these transactions are reported after they occur and may not reflect current holdings.